Recce Pharmaceuticals extends collaboration with Murdoch Children’s Research Institute, focusing on their Anti-Infective Research (AIR) Unit. Led by Dr. Sohinee Sarkar, the partnership aims to enhance preclinical programs and explore new indications for RECCE® 327. Their synergy emphasizes combatting antibiotic resistance and advancing infectious disease treatment, fostering groundbreaking discoveries for global health challenges.
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) has announced the extension of its collaboration with the Murdoch Children’s Research Institute (MCRI) to further advance its Anti-Infective Research (AIR) Unit. This partnership aims to optimize ongoing preclinical programs and explore new indications for future clinical trials in the development of synthetic anti-infectives.
Established in 2023, Recce’s dedicated AIR Unit, headed by Dr. Sohinee Sarkar, operates within MCRI’s advanced research facilities, demonstrating the shared commitment to pioneering innovation in anti-infective therapeutics.
The partnership has yielded significant progress in preclinical studies of Recce’s lead candidate, RECCE® 327, demonstrating efficacy against various life-threatening infectious pathogens, including Escherichia coli, Mycobacterium abscessus, Streptococcus pneumoniae, and Neisseria gonorrhoeae. Such collaborations are crucial in tackling antibiotic resistance, as emphasized by Professor Andrew Steer, Theme Director of Infection, Immunity, and Global Health at MCRI.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
The synergy between Recce’s AIR Unit and MCRI underscores the potential for impactful medical breakthroughs. Their joint efforts not only aim to advance anti-infective research but also prioritize improving patient outcomes and addressing global health challenges.
James Graham, CEO of Recce Pharmaceuticals, emphasized the alignment of their ongoing work with MCRI’s mission to combat antimicrobial resistance through innovative research. This collaborative approach holds the promise of transformative discoveries in infectious disease treatment.
